Table 1 Demographic and Baseline Characteristics
Median Age (range), y | 51.5 (34-75) |
Sex, male, n (%) | 8 (50) |
Median time since kidney transplantation (range), y | 12.8 (2.3-25.8) |
Number of previous renal transplantations (1st /2nd/3rd/4th) | 4/11/0/1 |
Cause of end-stage renal disease, n | |
Chronic Glomerulonephritis | 5 |
Polycystic Kidney Disease | 3 |
Alport-Syndrome | 4 |
Interstitial Nephritis | 3 |
Unknown | 1 |
CMV antibody status: (Donor (D+/-)/Recipient (R+/-); n | |
Low-risk (D - / R +) | 4 |
Intermediate risk (D + / R +) | 10 |
High-risk (D + / R -) | 2 |
EBV antibody status: (D unknown /R +) | 16 |
Type of Immunsuppressive used, n (%) | |
Tacrolimus | 8 (50) |
Cyclosporine | 7 (44) |
Sirolimus | 1 (6) |
Mycophenolate | 14 (88) |
Azathioprine | 1 (6) |
Steroids | 6 (38) |
Renal Transplant function | |
Median Creatinine, mg/dl | 1.27 (0.95-2.3) |
Median eGFR, ml/min per 1.73 m2 | 60 (25-87) |
HCV genotype, n | |
Ia | 1 |
Ib | 15 |
Median HCV RNA level (range), log10 IU/ml | 1.19 E6 (36600-9.4 E6) |
Previous HCV therapy (pegINF and/or ribavirin) n/N | 4/16 |
Stage of Liver disease | |
Liver biopsy available, n/N | 14/16 |
Stage of Fibrosis, n/N | |
• No or minimal (F0, F0-F1, or F1) | 2/14 |
• Moderate (F1-F2 or F2) | 10/14 |
• Severe (F3) | 2/14 |
Median body mass index (range), kg/m2 | 21.47 (16.43-31.25) |